CELEX: 62020TA0579
Language: en
Date: 2022-03-02 00:00:00
Title: Case T-579/20: Judgment of the General Court of 2 March 2022 — Genekam Biotechnology v Commission (Grant agreement concluded under the Seventh Framework Programme for research, technological development and demonstration activities (2007-2013) — Fibrogelnet project — Recovery of an amount receivable — Risk avoidance mechanism — Amount receivable effectively recovered from the Guarantee Fund — Decision establishing a pecuniary obligation and forming an enforceable decision — Article 299 TFEU — Competence of the author of the act — Termination of the applicant’s participation in the project — Eligible costs — Reports and deliverables)

16.5.2022   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 198/37
            
         
      Judgment of the General Court of 2 March 2022 — Genekam Biotechnology v Commission
      (Case T-579/20) (1)
      
      (Grant agreement concluded under the Seventh Framework Programme for research, technological development and demonstration activities (2007-2013) - Fibrogelnet project - Recovery of an amount receivable - Risk avoidance mechanism - Amount receivable effectively recovered from the Guarantee Fund - Decision establishing a pecuniary obligation and forming an enforceable decision - Article 299 TFEU - Competence of the author of the act - Termination of the applicant’s participation in the project - Eligible costs - Reports and deliverables)
      (2022/C 198/52)
      Language of the case: German
      
         Parties
      
      
         Applicant: Genekam Biotechnology AG (Duisburg, Germany) (represented by: S. Hertwig, lawyer)
      
         Defendant: European Commission (represented by: L. André, J. Estrada de Solà and R. Pethke, acting as Agents)
      
         Re:
      
      Application under Article 263 TFEU for annulment of Commission Decision C(2020) 5548 final of 7 August 2020 establishing a pecuniary obligation and forming an enforceable decision against the applicant for the amount of EUR 119 659,55, together with default interest, arising from the grant that it received in respect of the Fibrogelnet project.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Genekam Biotechnology AG to pay the costs, including those relating to the proceedings for interim measures.
               
            
         (1)  OJ C 414, 30.11.2020.